Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma.

Autor: Tondepu C; Regenerative Bioscience Science Center, University of Georgia, Athens, GA, 30602, USA., Karumbaiah L; Regenerative Bioscience Science Center, University of Georgia, Athens, GA, 30602, USA.; Division of Neuroscience, Biomedical & Translational Sciences Institute, University of Georgia, Athens, GA, 30602, USA.; Edgar L. Rhodes Center for ADS, College of Agriculture and Environmental Sciences, University of Georgia, Athens, GA, 30602, USA.
Jazyk: angličtina
Zdroj: Advanced healthcare materials [Adv Healthc Mater] 2022 Feb; Vol. 11 (4), pp. e2101956. Date of Electronic Publication: 2021 Dec 29.
DOI: 10.1002/adhm.202101956
Abstrakt: Glioblastoma (GBM) is a stage IV astrocytoma that carries a dismal survival rate of ≈10 months postdiagnosis and treatment. The highly invasive capacity of GBM and its ability to escape therapeutic challenges are key factors contributing to the poor overall survival rate. While current treatments aim to target the cancer cell itself, they fail to consider the significant role that the GBM tumor microenvironment (TME) plays in promoting tumor progression and therapeutic resistance. The GBM tumor glycocalyx and glycan-rich extracellular matrix (ECM), which are important constituents of the TME have received little attention as therapeutic targets. A wide array of aberrantly modified glycans in the GBM TME mediate tumor growth, invasion, therapeutic resistance, and immunosuppression. Here, an overview of the landscape of aberrant glycan modifications in GBM is provided, and the design and utility of 3D glycomaterials are discussed as a tool to evaluate glycan-mediated GBM progression and therapeutic efficacy. The development of alternative strategies to target glycans in the TME can potentially unveil broader mechanisms of restricting tumor growth and enhancing the efficacy of tumor-targeting therapeutics.
(© 2021 Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: